Published January 1, 2020 | Version v1
Journal article Open

Delivery of Small Molecule EF2 Kinase Inhibitor for Breast and Pancreatic Cancer Cells Using Hyaluronic Acid Based Nanogels

  • 1. Canakkale Onsekiz Mart Univ, Nanosci & Technol Res & Applicat Ctr NANORAC, Fac Sci & Arts, Dept Chem, Canakkale, Turkey
  • 2. Canakkale Onsekiz Mart Univ, Fac Sci & Arts, Dept Chem, Nat Prod & Drug Res Lab, Canakkale, Turkey

Description

Purpose To evalauted natural polymeric biomaterials including hyaluronic acid (HA) and its copolymeric form HA:Suc nanoparticles (NPs) as drug carrier systems for delivery of hydrophobic small molecule kinase EF2-kinase inhibitor in breast and pancreatic cancer cells. Methods In vitro cellular uptake studies of Rhodamine 6G labaled HA:Suc nanoparticles were evaluated by using flow cytometry analysis and fluorescent microscopy in breast (MDA-MB-231 and MDA-MB-436) and pancreatic cancer cells (PANC-1 and MiaPaca-2). Besides, in vitro release study of compound A (an EF2-kinase inhibitor) as a model hydrophobic drug was performed in the cancer cells. Results These biological evaluation studies indicated that HA and HA:Suc NPs provided a highly effective delivery of compound A were into breast and pancreatic cancer cells, leading to significant inhibition of cell proliferation and colony formation of breast and pancreatic cancer cells. Conclusion HA-sucrose NPs incorporating an EF2-Kinase inhibitor demonstrate significant biologic activity in breast and pancreatic cancer cells. This is the first study that shows natural polymeric drug carriers succesfully deliver a hydrofobic cancer drug into cancer cells.

Files

bib-6474ec4c-8be8-43ae-867b-f42fef817490.txt

Files (234 Bytes)

Name Size Download all
md5:ced72bbcc925812b1111e959efbbb872
234 Bytes Preview Download